Parabolis

Parabolis is a company developing microrobotic thrombolytics specifically engineered to target and enhance the treatment of deep vein thrombosis (DVT). The company leverages advanced microfluidics and microsized materials to create a novel solution that aims to improve upon traditional high-dose thrombolytic therapies. By focusing on targeted, controllable delivery, Parabolis seeks to address the limitations of conventional treatments for DVT, with plans to expand its therapeutic platform to target a broader range of cardiovascular diseases in the global thrombosis market.

The company is co-founded by Yimo Yan and Josh Mesfin, who combine expertise in microfluidics, biomaterial design, and cardiovascular translational research. Parabolis has been recognized for its innovation in the field, including receiving funding for its microrobot-mediated thrombolysis research. The venture aims to provide a more effective, localized approach to treating thrombosis, addressing a significant medical challenge that affects millions of individuals worldwide.